Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
197
datasets available to search
ShareScore release 0.7.1
Dataset results
197 results for “BCMA”
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
<p>BCMA-targeted CAR-T therapy has shown potent treatment outcomes in treating multiple myeloma (MM), a disease characterized by malignant bone marrow (BM) plasma cells. However, the remodeling of MM microenvironment after CAR-T therapy remains poorly understood. Here, we report the reconstitution of MM microenvironment by obtaining single-cell transcriptomes for paired BM specimens (n = 14) from 7 MM patients before (<em>i.e.</em>, baseline, ''day −4'') and after (<em>i.e.</em>, ''day 28'') post-lymphodepleted BCMA CAR-T therapy. Our analysis revealed heterogeneity in driver gene expression among MM cells, even those harboring the same cytogenetic abnormalities. The best overall responses of patients over the 15-month follow-up are positively correlated with the abundance and targeted cytotoxic activity of CD8<sup>+</sup> effector CAR-T cells on day 28 after CAR-T cell infusion. Additionally, favorable responses are associated with attenuated immunosuppression mediated by regulatory T cells (Tregs), enhanced CD8<sup>+</sup> effector T cell cytotoxic activity, and elevated type 1 conventional dendritic cell (cDC1) antigen presentation ability. DC re-clustering inferred intramedullary-originated cDC3s with extramedullary migration. Cell-cell communication network analysis indicated BCMA CAR-T therapy mitigates BAFF/GALECTIN/MK pathway-mediated immunosuppression and activates MIF pathway-mediated anti-MM immunity. Our study sheds light on MM microenvironment dynamics after BCMA CAR-T therapy, offering clues for predicting treatment responsivity.</p>
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)
ClinicalTrials.gov study NCT03288493. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03338972. IPD Sharing: Not stated. Countries: 1. Publications: 1.
APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma
ClinicalTrials.gov study NCT03287804. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
ClinicalTrials.gov study NCT06371040. IPD Sharing: YES. Countries: 1. Publications: 0.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov study NCT03548207. IPD Sharing: Not stated. Countries: 2. Publications: 11.
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethason
ClinicalTrials.gov study NCT04181827. IPD Sharing: YES. Countries: 16. Publications: 8.
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
ClinicalTrials.gov study NCT03602612. IPD Sharing: YES. Countries: 1. Publications: 0.
A Prospective, Multicenter, Diagnostic Study Evaluating 68Ga-BCMA PET/CT for Targeting BCMA Expression in Multiple Myeloma.
ClinicalTrials.gov study NCT07319897. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Reconstitution of the multiple myeloma microenvironment following lymphodepletion with BCMA CAR-T therapy
Open the record for dataset details and reuse information.
Dataset for Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL and IL-6 in supporting antibody-producing cells in different tissues
<p>This dataset is related to "Unique and redundant roles of mouse BCMA, TACI, BAFF, APRIL and IL-6 in supporting antibody-producing cells in different tissues" (Eslami M, Schuepbach-Mallpell S, Diana D, Willen L, Kowalczyk-Quintas C, Desponds C, Peter B, Vigolo M, Renevey F, Donzé O, Lüther SA, Yalkinoglu Ö, Alouche N, Schneider P).</p>
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
ClinicalTrials.gov study NCT04322292. IPD Sharing: NO. Countries: 1. Publications: 1.
T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT04662099. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
ClinicalTrials.gov study NCT04295018. IPD Sharing: NO. Countries: 1. Publications: 1.
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma
ClinicalTrials.gov study NCT03070327. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
ClinicalTrials.gov study NCT03549442. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
ClinicalTrials.gov study NCT04706936. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT05698303. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
ClinicalTrials.gov study NCT07094048. IPD Sharing: UNDECIDED. Countries: 1. Publications: 18.
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody.
ClinicalTrials.gov study NCT04309981. IPD Sharing: NO. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.